ArticleJCO precision oncology2017
Clinical Use of Precision Oncology Decision Support.
Article in JCO precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Implementation of precision medicine in treating non-communicable diseases: a systematic review.Journal of translational medicine · 2025Pooled it
- Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.Journal of translational medicine · 2022Trial
- Prognosis and treatment response stratification according to loss of proofreading (LOP)Journal for immunotherapy of cancer · 2025Article
- Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131).Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- The present and future of precision oncology and tumor-agnostic therapeutic approaches.The oncologist · 2025Review
- Impact of travel costs on disparities in precision oncology clinical trials.ESMO real world data and digital oncology · 2025Article
- Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.Veterinary sciences · 2024Review
- Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.Journal of hepatology · 2024Article
- Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital.JAMA network open · 2023Article
- Actionability classification of variants of unknown significance correlates with functional effect.NPJ precision oncology · 2023Article
- Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience.JCO precision oncology · 2021Article
- Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort.International journal of medical informatics · 2020Article
- Medical oncologists' perspectives of the Veterans Affairs National Precision Oncology Program.PloS one · 2020Article
- A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants.Frontiers in cell and developmental biology · 2020Review
- Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology.JCO clinical cancer informatics · 2019Review
- Next-generation sequencing for the general cancer patient.Clinical advances in hematology & oncology : H&O · 2019Review
- Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.The oncologist · 2019Article
- Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology.JCO precision oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposePrecision oncology is hindered by the lack of decision support for determining the functional and therapeutic significance of genomic alterations in tumors and relevant clinically available options. To bridge this knowledge gap, we established a Precision Oncology Decision Support (PODS) team that provides annotations at the alteration-level and subsequently determined if clinical decision-making was influenced.
methodsGenomic alterations were annotated to determine actionability based on a variant's known or potential functional and/or therapeutic significance. The medical records of a subset of patients annotated in 2015 were manually reviewed to assess trial enrollment. A web-based survey was implemented to capture the reasons why genotype-matched therapies were not pursued.
resultsPODS processed 1,669 requests for annotation of 4,084 alterations (2,254 unique) across 49 tumor types for 1,197 patients. 2,444 annotations for 669 patients included an actionable variant call: 32.5% actionable, 9.4% potentially, 29.7% unknown, 28.4% non-actionable. 66% of patients had at least one actionable/potentially actionable alteration. 20.6% (110/535) patients annotated enrolled on a genotype-matched trial. Trial enrolment was significantly higher for patients with actionable/potentially actionable alterations (92/333, 27.6%) than those with unknown (16/136, 11.8%) and non-actionable (2/66, 3%) alterations (
conclusionOver half of alterations annotated were of unknown significance or non-actionable. Physicians were more likely to enroll a patient on a genotype-matched trial when an annotation supported actionability. Future studies are needed to demonstrate the impact of decision support on trial enrollment and oncologic outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.